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Experiences with array-based sequence capture;
toward clinical applications
Rowida Almomani1, Jaap van der Heijden1, Yavuz Ariyurek1,2, Yuching Lai2, Egbert Bakker1,
Michiel van Galen1,2, Martijn H Breuning1 and Johan T den Dunnen*,1,2
Although sequencing of a human genome gradually becomes an option, zooming in on the region of interest remains attractive
and cost saving. We performed array-based sequence capture using 385K Roche NimbleGen, Inc. arrays to zoom in on the
protein-coding and immediate intron-ﬂanking sequences of 112 genes, potentially involved in mental retardation and congenital
malformation. Captured material was sequenced using Illumina technology. A data analysis pipeline was built that detects
sequence variants, positions them in relation to the gene, checks for presence in databases (eg, db single-nucleotide
polymorphism (SNP)) and predicts the potential consequences at the level of RNA splicing and protein translation. In the
samples analyzed, all known variants were reliably detected, including pathogenic variants from control cases and SNPs derived
from array experiments. Although overall coverage varied considerably, it was reproducible per region and facilitated the
detection of large deletions and duplications (copy number variations), including a partial deletion in the B3GALTL gene from a
patient sample. For ultimate diagnostic application, overall results need to be improved. Future arrays should contain probes
from both DNA strands, and to obtain a more even coverage, one could add fewer probes from densely and more probes from
sparsely covered regions.
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INTRODUCTION
For many years, the ampliﬁcation of target sequences by PCR,
followed by Sanger sequencing, has been the gold standard for
screening of variants in terms of both read length and accuracy of
sequencing.1 However, when it comes to conditions with highly
heterogeneous etiology, a large number of different genes need to be
screened for mutations. In such cases, gathering information becomes
laborious, expensive and time-consuming. There are many examples
of diseases that can be caused by mutations in many different genes,
including mental retardation (MR),2 Charcot–Marie–Tooth disease,3
cardiomyopathy,4 retinitis pigmentosa,5 autism,6 hearing loss7 and
congenital disorders of glycosylation.8 Extensive resequencing of many
disease-associated genes is required to explore, at the sequence and
structural level, the genomic variation that might be involved in
causing such diseases.
Several next-generation sequencing (NGS) platforms are now
available and they have allowed the sequencing and analysis of large
numbers of genes in one experiment,9–11 and are able to generate a
massive amount of sequence data and have considerably reduced
the cost of DNA sequencing.12 However, although NGS platforms
have enormously increased throughput and have permitted whole-
genome sequencing, high cost still prevents routine whole human
genome resequencing projects. Therefore, zooming in on the region of
interest is an attractive option. In addition, it circumvents the problem
of identifying variants in genes for which the analyses were not
intended (with associated ethical problems).
Microarray-based genomic selection combined with massively par-
allel high-throughput sequencing is the method of choice to analyze
large numbers of genes in a more comprehensive and cost-effective
manner.13–15 We have used custom high-density microarrays
(Roche NimbleGen, Inc., Madison, WI, USA) for the enrichment of
112 distinct genes potentially involved in MR and congenital mal-
formation, followed by sequencing on the Illumina Genome Analyzer
I platform (Illumina, San Diego, CA, USA).
The ﬁrst aim of our study was to apply and validate the array-based
enrichment method as an efﬁcient and convenient strategy to capture
any desired portion of the human genome. The second aim was to
accelerate the detection of sequence and copy number variations
(CNV) in the selected candidate genes with lower costs, especially
for the genes that are potentially involved in MR.
MATERIALS AND METHODS
Sample selection and validation
Six DNA samples were used in this study, including two controls containing
known pathogenic variants. Sample S-2 contains a known MECP2 (OMIM
300005) pathogenic point mutation (c.538C4T); the second sample, patient S-6,
carries a large deletion spanning exons 8–15 in one allele and a splice site
mutation (c.660+1G) at the other allele of the B3GALTL (OMIM 610308) gene.
The other four DNA samples were from patients with MR with an unknown
cause. Single-nucleotide polymorphism (SNP) array data were available for two
samples: S-7 with 250K Nsp Affymetrix and S-5 with 317K Illumina data. We
used these data to validate the sequences obtained after capture-array and
Received 22 April 2010; revised 16 July 2010; accepted 20 July 2010; published online 24 November 2010
1Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands and 2Leiden Genome Technology Center, Leiden University Medical Center,
Leiden, The Netherlands
*Correspondence: Professor Dr JT den Dunnen, Center for Human and Clinical Genetics and Leiden Genome Technology Center, Leiden University Medical Center, Postzone
S4-P, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. Tel: +31 71 5269501; Fax: +31 71 526 8285; E-mail: ddunnen@HumGen.nl
European Journal of Human Genetics (2011) 19, 50–55
& 2011 Macmillan Publishers Limited All rights reserved 1018-4813/11
www.nature.com/ejhgIllumina sequencing. Causative large deletions and duplications had been
previously excluded by SNP array testing in S-3, S-5, S-7 and S-8.
Exon array design
Microarrays with 385K probe capacity (Roche NimbleGen, Inc.) were used
to capture all exons, the splice site and the immediately adjacent intron
sequence of 112 human genes. On the basis of searches in OMIMand literature,
we selected 112 human genes known to cause MR, either as part of a
known syndrome or in isolation (Supplementary Table 1). Primary sequence
data from all exons were extracted from NCBI’s genome (Build 36).
Microarrays were designed by Roche NimbleGen, Inc. with long oligonucleotide
probes (54–99 nucleotides) that span each target region, overlapped and
shifted on an average of seven bases.13 The oligonucleotides were designed to
achieve isothermal hybridization across the arrays capturing one strand only.
All highly repetitive regions were excluded from the probe selection in order to
avoid nonspeciﬁc capturing of genomic regions. Using all criteria listed, for 2%
of the target sequences, no capture probe could be designed (note that,
theoretically, these sequences can be covered partly through capture
from directly ﬂanking unique sequences). Four of the arrays were reused at
least twice.
Genomic DNA library preparation and target capture
The methods used for target capture, enrichments and elution followed
previously described protocols with slight modiﬁcations (Roche NimbleGen,
Inc.).16 Genomic DNA (20–10mg) was fragmented using a nebulizer or
Bioruptor according to instructions from the manufacturer to yield fragments
from 250–1000bp (nebulization) or 250–600bp (Bioruptor). Adapter
oligonucleotides from Illumina (single reads) were ligated to the ends. After
the ligation was completed, successful adapter ligation was conﬁrmed by PCR.
The DNA-adapter ligated fragments were then hybridized to the sequence
capture microarray for 65h. After hybridization and washing, the DNA
fragments bound to the array were eluted, using 300ml of the elution buffer
(Qiagen, Valencia, CA, USA) on each array. A gasket (Agilent) was applied and
placed on the thermal elution device (homemade) for 20min at 951C. We
repeated this process once by adding 200ml of elution buffer (Qiagen). DNA
from each eluted sample was enriched by 18-cycle PCR using a high-ﬁdelity
polymerase and a single primer pair corresponding to the Illumina adapters
ligated earlier.
Check enrichments by qPCR
To verify successful hybridization capture, we performed qPCR (quantitative
PCR) on DNA samples (S-2, S-3, S-5, S-7, S-6 and S-8) before and after array
enrichment. The primers ampliﬁed ﬁve loci from MBL2, DMD and BRCA1
(100bp) as negative controls (no capture probes on the array) and four loci
from MECP2, CREBBPand NSD1 genes as positive controls (capture probes on
the array) (Supplementary Table 2). All primers for qPCR were designed using
Primer 3 (http://frodo.wi.mit.edu/).
The qPCR assays were performed in triplicate in the Lightcycler using
384-well plates (Roche NimbleGen, Inc.) in 10ml total volume: 5mlo f2   SYBR
Green master Rox (Roche NimbleGen, Inc.), 0.25ml of each primer (10pmol/
ml), 2ml of DNA template and 2.5ml of ultrapure water. The thermo-cycling
protocol was carried out as follows: 10min at 951C, 45 cycles of 10s at 951C,
30s at 601C, 20s at 721C and 5min at 721C, followed by melting curve analysis
in order to determine the speciﬁc and nonspeciﬁc ampliﬁed products and other
artifacts that might interfere with CP values. To calculate the relative fold
enrichment of the targeted regions, we compared ampliﬁcation of the positive
versus negative controls. The relative fold enrichment, R, was calculated using the
values of DCP (ie, the difference between average CP of non-captured and
average CP of captured samples) according to R¼EN,w h e r eE is the efﬁciency
of the qPCR assay for a particular amplicon and N¼DCP (crossing point).
DNA sequencing
The eluted enriched DNA fragments were sequenced using the Illumina GAI
platform at the Leiden Genome Technology Center (LGTC). Single-end
sequencing of 36 or 50 nucleotides was performed following the instructions
of the manufacturer.
Reads mapping and data analysis
Sequence read mapping was carried out by ELAND and ELAND-extended
programs, which were a part of the Illumina GAI data analysis package. Only
reads of high-quality scores were mapped to the human reference genome
(NCBI, BUILD 36.2), allowing up to two mismatches. We created different Perl
scripts to extract and process data from the ELAND ﬁles. Coverage was
calculated at the target level (gene–exons), the nucleotide level and at the per
probe region. SNP calling was performed by searching for nucleotides dis-
cordant with the reference genome with a base call quality score of 30 (99.9%
base call accuracy), a read depth of 8 or greater and the variant allele larger than
30% of the total coverage. Thereafter, all variants were checked for their
presence in known databases, for example, dbSNP. Perl scripts were designed to
predict the potential consequences at the level of RNA splicing and protein
translation on the basis of Ensemble v.51. Furthermore, we designed a Perl
script to facilitate detection of small deletions/insertions (up to three nucleo-
tides). All Perl scripts are available on request.
Sanger sequencing
A total of 21 variants detected by Illumina GAI analyzer were selected and
conﬁrmed by Sanger sequencing using the standard Sanger sequencing protocol
at the Leiden Genome Technology Center (LGTC). The primer sequences (with
M13 tail) used are shown in Supplementary Table 3.
RESULTS
The methodology used starts with fragmentation of the genomic
DNA. Linker and primer addition can then be performed either
before or after array-capture target enrichment. To facilitate limited
ampliﬁcation of the expected low-yield array elution, we decided to
perform full Illumina sample preparation before array capture. Initi-
ally, experiments were conducted using 20mg genomic DNA, later
we reduced this to 10mg. We used qPCR, comparing targeted (four
positive controls) and non-targeted regions (ﬁve negative controls), to
check successful array enrichment and to estimate the fold enrichment
obtained (see Supplementary Tables 4 and 5 for examples). As
enrichment varies signiﬁcantly from locus to locus, we tested multiple
loci to obtain an accurate estimate. Samples in which qPCR did not
indicate clear enrichment (4100 ) were discarded. The ultimate
enrichments achieved varied from experiment to experiment with a
tendency to increase over time, indicating that lab experience is an
important aspect of the array capture technology. As the fold enrich-
ments determined by qPCR correlate positively with the average
sequence depth obtained, we conclude that qPCR provides an effective
and cost-saving check for successful enrichment (examples are listed
in Supplementary Tables 4 and 5).
Sequence data
The custom arrays used contained 112 different human genes that are
known to be or potentially involved in MR and congenital malforma-
tion. Samples were run on one channel of the Illumina GAI. For
sequence analysis, we used only those QC-ﬁltered reads that map back
uniquely to the reference sequence (M0) or with one or two
mismatches (M1, M2) (Figure 1). Using these settings, 85–92% of
the targeted nucleotides were covered by at least eight reads (Table 1)
and 94–98% by at least one read (note that for 2% of the targeted
sequences, no probe could be designed, see M&M). Effectively, this
means that for 78% of the targeted sequences on the array, coverage
was sufﬁcient (420 ) to detect any variants that were present.
Two of the samples had been previously analyzed using SNP arrays.
The region selected using the capture array included 67 different SNPs
that had been present on the SNP arrays. We observed a perfect
agreement (100%) between array-based SNP calls and those obtained
using NGS (67/67 variants) (Supplementary Table 6).
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we included one sample from a female patient (S-2) harboring
a dominant pathogenic point mutation in the MECP2 gene,
(c.538C4T) on the X chromosome. Our results clearly detected the
change in the heterozygous state (Supplementary Table 7). Similarly,
we detected a homozygous change in the B3GALTL gene in a Peter’s
Plus patient (c.660+1G4A, Supplementary Table 7, see below).
We next selected 21 variants detected in samples S-2, S-3, S-5, S-7
and S-8 and checked these by traditional Sanger sequencing. We
were able to conﬁrm 21 of the 21 variants, including their status being
homozygous or heterozygous (Supplementary Table 7). The analysis
of the variants found in all 112 genes of the patients did not reveal a
clear cause of their MR Supplementary Table 8 and 9.
CNV
Changes that cannot be easily detected using the sequence itself
include deletions and duplications (CNVs). However, such variants
can be expected to yield quantitative changes in coverage. To deter-
mine whether overall coverage can be used to detect quantitative
changes, we ﬁrst analyzed the 39 genes located on the X chromosome.
Indeed, when coverage was normalized using autosomal genes
(Figure 2a), samples from females showed a clearly higher X-chromo-
some coverage compared with male samples (Figure 2b). Further-
m o r e ,a se x p e c t e d ,t h eg e n eo nt h eYc h r o m o s o m e( NLGN4Y)g a v en o
coverage in the female sample (Figure 2b). To determine the sensitivity
of our method for detecting smaller CNVs, we carefully analyzed a
sample from a compound heterozygous patient (S-6) carrying a
partial deletion (exons 8–15) and a splice site mutation
(c.660+1G4A, intron 8) in the B3GALTL gene. The splice site
mutation was evident as no wild-type sequence was present. The
presence of a deletion emerged as, compared with other samples, we
observed a signiﬁcantly lower average coverage for the B3GALTL gene
(53  versus 155 ,1 5 0  ,1 4 0  ) (Figure 2c). In addition, although the
splice site mutation in exon 8 was detected in the ‘homozygous’ state
(similar to all nine variants downstream), we observed variants in the
ﬁrst exons (1–7) also in heterozygous state (Supplementary Table 10).
These data show that not only have we obtained an excellent
speciﬁcity of the capture process but we have also been able to
distinguish between male and female samples.
DISCUSSION
Array-based genomic selection offers several advantages for large-scale
targeted DNA isolation over other approaches such as PCR-based
methods (long-range PCR or multiplexed short PCR),17–19 selector
technology20,21 and BACs technology.22 PCR-based methods become
laborious, time-consuming and costly if hundreds to thousands of
regions (exons) need to be ampliﬁed, especially if all the sequences are
required. Furthermore, when PCRs are multiplexed, it becomes
difﬁcult to check successful ampliﬁcation per fragment, the chance
of obtaining artifacts increases and equimolar loading before sequen-
cing becomes very difﬁcult. New approaches for massive individual
PCR have been introduced recently23 but experiences with these are
still limiting. Selector technology20,21 seems attractive but it largely
depends on proper in-house probe design, and experience thus far is
very limited. Successful genomic selection using BACs has been
demonstrated but has several limitations. As a BAC is the unit of
selection, multiple BACs are required to isolate discontinuous regions
of interest.
In this study, we have tested array-based sequence capture to
determine the sequence of 112 genes potentially involved in MR.
We show that array-based sequence capture technology is an efﬁcient,
quick and reliable method for the parallel sequencing of a range of
genes of interest. Known variants (array-based calls) for 67 SNPs
matched perfectly with those obtained using NGS Supplementary
Table 6. Two positive controls with known pathogenic changes in the
MECP2 gene (sample S-2) and B3GALTL gene (sample S-6) were
readily detected. In addition, 21/21 selected variants found in the ﬁve
samples analyzed could be conﬁrmed using Sanger sequencing (Sup-
plementary Table 7). Sequence coverage of the nucleotide of interest is
critical for reliably detecting sequence changes. If coverage is too low,
both false positives (caused by sequence errors) and false negatives (if
only one allele from a heterozygous sample is observed) will occur.
The coverage we obtained differs signiﬁcantly not only between
targeted genomic regions (genes) but also between different samples
(Supplementary Table 1, Figure 2a). As the overall methodology
is rather complex, particularly the collection of the hybridized array-
enriched DNA sequences, the difference between samples is most
probably inﬂuenced by technical factors such as variations in hybri-
dization, washing conditions and potential reuse of the capture
array. Furthermore, coverage is inﬂuenced by array design, inclu-
ding probe sequence (melting temperature, GC content), probe
density and spacing (Supplementary Table 1). Our data show that
AT-rich regions (455%), regions with an overall low probe density
(o3) and small exons (on average 90bp) yield a low coverage,
which also varies signiﬁcantly between experiments. For a second-
generation capture array, the results obtained could be used to change
the probe density, that is, decreased in well-covered and increased in
low-covered regions.
Our data show that longer reads (50bp) improve accuracy and
selectivity of read mapping to the reference genome, which inﬂuenced
the SNP calling by having less false positives and slightly better
coverage.
As CNVs (deletions/duplications) are a signiﬁcant cause in the
etiology of MR,24 we tested the feasibility of detecting large CNVs
using array capture and NGS. Our results indicate that, if coverage is
sufﬁciently high, array capture can also be used to detect such
Figure 1 Detection of sequence variants. A total of 32 nucleotide NGS reads
(top, sequence mismatches in red) aligned with the genomic reference
sequence (bottom). The center of the alignment shows a variant present in
the heterozygous state. ‘ n’ behind the read indicates how many identical
reads were obtained.
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chromosome that gave no coverage in females (Figure 2b), whereas
the 39 X-linked genes when compared with the 69 autosomal genes
yielded overall 50% lower coverage in male samples (Figure 2b).
Another example derives from a sample containing a partial B3GALTL
gene deletion on one allele (exons 8–15) and a splice site mutation on
the other allele (c.660+1G4A). Although coverage over the entire
gene seems reduced (experimental variation/coincidence), coverage
for the second half of the gene clearly drops below that of normal
(Figure 2d). An algorithm for detecting local deviations from the
average coverage is currently under development.
Regarding probe design (performed by Roche NimbleGen, Inc.), it
should be noted that all array probes are from one strand (coding
DNA strand) and thus DNA molecules from only the non-coding
strand are captured. This has several consequences. First, the sequence
obtained is from one strand only, whereas for diagnostic applications,
quality assurance requires that sequences be obtained in forward and
reverse orientation. Sequencing this one strand in both directions is
partly fooling oneself. Second, we observed that the sequences
obtained relative to the array probes extend in a 5¢ but not in a 3¢
direction. The most probable cause for the latter is steric hindrance
during array hybridization, preventing non-hybridizing tails at the
surface side of the array. When capture probes are attached with their
3¢ ends, this has consequences for probe design at the edges of the
targeted regions; on the 5¢ side, coverage will be signiﬁcantly better
than on the 3¢ side. Both effects could be overcome simply by reversing
the probe sequence of every other nucleotide on the array. Theoreti-
cally, this would also mean that the overall yield of enriched DNA
would double, as both strands from the sample will be captured.
To save costs, we have reused the arrays up to three times by
hybridizing different samples. The danger of this approach is of course
contamination, if hybridized DNA from a previous experiment is
not eluted completely. Indeed, in some experiments, we observed
low-level contamination, for example, through heterozygous calls
from X-chromosome sequences in male samples. It should be noted,
however that cross-contamination can be easily controlled when
samples containing differently tagged linkers are used in subsequent
experiments.
Using the current design, low coverage was obtained mainly at the
edges of the regions targeted, especially the 3¢ side (see above), that is,
direct gene ﬂanking or intronic regions. Although coverage varied
widely, 78% of all regions targeted and present on the array were
covered effectively by the sequence obtained. Note that there is a clear
correlation between fragment size of the genomic DNA used and the
coverage, the larger the fragment size used the lower the target
coverage achieved, as more ﬂanking DNA is captured. Especially for
array-based capture, because of the steric hindrance described, this
effect will be signiﬁcant near the array-attached end of a probe-
targeted region. Assuming that second-generation capture arrays will
be more effective (ie, complete and with even coverage) and sequence
power will improve further, it should soon be possible to sequence-
tag, mix and simultaneously analyze different samples in one experi-
ment, giving a signiﬁcant cost reduction.
Recently in-solution capture was presented as an alternative to
array-based capture.25 Besides advantages of simplicity, a reduced
workload and a potential for automation, when attempted, in-solu-
tion capture will not show the effect of steric hindrance we observed.
However, capturing both strands would be complicated by the fact
that capture probes will hybridize with each other. Initial experiences
in our lab with in-solution capture were successful and for future
projects we will change to this approach.
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European Journal of Human GeneticsOverall, we conclude that array-based sequence capture followed by
NGS offers a versatile tool for successfully selecting sequences of
interest from a total human genome. The approach will be especially
helpful in speeding up the identiﬁcation of the pathogenic muta-
tion(s) in diseases in which the genomic region to be scanned is large.
Our results indicate that the methodology can still be improved, in
particular, with respect to probe design, obtaining a more even
coverage of the targeted regions. On the basis of initial experiences
and publications, we expect that array capture will be quickly replaced
by in-solution capture. Ultimately, the cost of this approach is
determined by the minimal coverage, which in turn determines the
sensitivity required for the detection of potential sequence variants.
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